Subscribe: NIH Funding Opportunities (Notices, PA, RFA)
http://grants.nih.gov/grants/guide/newsfeed/fundingopps.xml
Preview: NIH Funding Opportunities (Notices, PA, RFA)

NIH Funding Opportunities (Notices, PA, RFA)



Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.



Published: Fri, 17 Nov 2017 01:33:55 EST

 









Notice of Correction to RFA-CA-17-035 "Pre-Cancer Atlas (PCA) Research Centers (U2C)"

Fri, 17 Nov 2017 10:50:48 EST

Notice NOT-CA-18-022 from the NIH Guide for Grants and Contracts






Notice of Change in Participant Eligibility for PAR-17-051 "Postbaccalaureate Research Education Program (PREP) (R25)"

Wed, 15 Nov 2017 02:24:01 EST

Notice NOT-GM-18-007 from the NIH Guide for Grants and Contracts



Notice of NIGMS Participation in PA-18-314 "Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp)"

Wed, 15 Nov 2017 04:40:07 EST

Notice NOT-GM-18-010 from the NIH Guide for Grants and Contracts






Notice of Upcoming Webinar for the Strong Heart Study (SHS) - Coordinating Center (CC) Solicitation

Thu, 16 Nov 2017 03:28:39 EST

Notice NOT-HL-17-562 from the NIH Guide for Grants and Contracts



2018 NIH Regional Seminar on Program Funding and Grants Administration - Early Registration Rates Available Now

Fri, 17 Nov 2017 10:32:59 EST

Notice NOT-OD-18-013 from the NIH Guide for Grants and Contracts



NIH will Make the Project Outcomes Section of all Interim and Final RPPRs Submitted on or After October 1, 2017 Available via the NIH RePORTER

Thu, 16 Nov 2017 10:50:12 EST

Notice NOT-OD-18-103 from the NIH Guide for Grants and Contracts



Pathogenesis of Age-Related HIV Neurodegeneration (R01 Clinical Trial Not Allowed)

Mon, 13 Nov 2017 02:09:32 EST

Funding Opportunity RFA-AG-18-023 from the NIH Guide for Grants and Contracts. NeuroHIV is at an inflection point, with an urgent need to understand the mechanisms that cause and modulate the CNS impairment in the era of antiretroviral therapies.



Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33)

Thu, 16 Nov 2017 09:21:10 EST

Funding Opportunity RFA-AT-18-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications to examine the impact of behavioral interventions within the context of states plans for use of the SAMHSA Opioid STR grant funds authorized under the 21st Century Cures Act. Applications are encouraged for studies that examine the impact of interventions such as mindfulness meditation, cognitive behavioral therapy, or multi-disciplinary rehabilitation for primary or secondary prevention for opioid use disorder (OUD) or as an adjunct to medication assisted treatment (MAT) of OUD. Applications that emphasize treatment of the comorbidity of OUD and chronic pain are of particular interest.



The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)

Tue, 14 Nov 2017 11:03:26 EST

Funding Opportunity RFA-CA-18-001 from the NIH Guide for Grants and Contracts. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.



Shedding light on the dark genome: Long Non-coding RNA in Cardiovascular, Lung, Blood, and Sleep Research (R01 - Clinical Trial Not Allowed)

Fri, 17 Nov 2017 11:08:12 EST

Funding Opportunity RFA-HL-19-011 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to foster research on human long non-coding RNAs (lncRNAs) to understand their roles in controlling the gene regulatory networks underpinning normal Heart, Lung, Blood and Sleep (HLBS) homeostatic and disease processes.



Limited Competition: RCMI Research Coordination Network (RRCN) (U54)

Fri, 17 Nov 2017 01:33:55 EST

Funding Opportunity RFA-MD-18-001 from the NIH Guide for Grants and Contracts. The RCMI Research Coordination Network (RRCN), formerly known as the RCMI Translational Research Network (RTRN), was established in 2007 to enhance collaboration across RCMI institutions. The network is designed to engage all stakeholders in the RCMI institutions, increase the quality and efficiency of basic biomedical, behavioral, and clinical research, facilitate study participant recruitment and retention, and increase the efficiency of the implementation and dissemination of research advances to improved health outcomes among minority and health disparity populations. Maintaining the longstanding networking and collaboration with the RCMI grantee community is key to the continued success of this program.



Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-Clinical Trial Required)

Tue, 14 Nov 2017 10:48:39 EST

Funding Opportunity RFA-MH-18-700 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions.



Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required)

Tue, 14 Nov 2017 10:48:44 EST

Funding Opportunity RFA-MH-18-701 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions.



Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required)

Tue, 14 Nov 2017 10:48:47 EST

Funding Opportunity RFA-MH-18-702 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.



Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required)

Tue, 14 Nov 2017 10:48:51 EST

Funding Opportunity RFA-MH-18-703 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, RFA-MH-18-702.



Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)

Tue, 14 Nov 2017 10:48:55 EST

Funding Opportunity RFA-MH-18-704 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting "go/no-go" milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.



Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33- Clinical Trial Required)

Tue, 14 Nov 2017 10:48:59 EST

Funding Opportunity RFA-MH-18-705 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.



Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)

Tue, 14 Nov 2017 10:49:03 EST

Funding Opportunity RFA-MH-18-706 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study.



Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01- Clinical Trial Required)

Tue, 14 Nov 2017 10:49:07 EST

Funding Opportunity RFA-MH-18-707 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit.



Trophoblast Differentiation and Function (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:13:11 EST

Funding Opportunity PA-18-047 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. It is anticipated that fundamental knowledge gained by this research will act as a solid foundation to hasten treatments for a number of placental-based pregnancy disorders, such as implantation failure, frequent pregnancy loss, preeclampsia, fetal growth restriction, and preterm birth.



Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:17:00 EST

Funding Opportunity PA-18-048 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications. This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017.



Fertility Status as a Marker for Overall Health (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:20:37 EST

Funding Opportunity PA-18-049 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program.



Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:22:28 EST

Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.



International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional)

Wed, 15 Nov 2017 09:24:24 EST

Funding Opportunity PA-18-065 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas(http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The NIH R03 activity code supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.



International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:27:06 EST

Funding Opportunity PA-18-066 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code.



Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional)

Wed, 15 Nov 2017 09:29:26 EST

Funding Opportunity PA-18-067 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving andthe drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of early stage efficacy, effectiveness or services research that will provide intervention pilot and/or feasibility data that is a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols; rather, any development work must be imbedded within a pilot/feasibility study.Of particular interest are prevention interventions targeting the healthcare system.



Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional)

Wed, 15 Nov 2017 09:33:59 EST

Funding Opportunity PA-18-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies, designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches.



Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional)

Wed, 15 Nov 2017 09:44:58 EST

Funding Opportunity PA-18-069 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages small grant applications (R03) to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.



Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:46:49 EST

Funding Opportunity PA-18-070 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.



Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional)

Wed, 15 Nov 2017 09:48:32 EST

Funding Opportunity PA-18-071 from the NIH Guide for Grants and Contracts. This FOA provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent.



AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)

Wed, 15 Nov 2017 09:53:26 EST

Funding Opportunity PA-18-072 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug abuse research on HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug abuse and HIV/AIDS that can be carried out in a short period of time with limited resources. Applications under this FOA are welcomed from all areas of HIV/AIDS research that NIDA supports.



Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseases (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 09:54:59 EST

Funding Opportunity PA-18-093 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, aging, and mitochondrial disease transmission to offspring. The overarching goal is to gain fundamental insight into the role of mitochondria and long-term consequences of their dysfunction in the oocyte, and to develop therapeutic or alternative approaches to treat mitochondrial dysfunction for improving oocyte quality and competency, and health of the resultant offspring. It is anticipated that the results from studies supported by this FOA will provide women, suffering from infertility or subfertility and other illnesses due to mitochondrial dysfunction, practical approaches to enhance their fertility and the well-being of their offspring. This funding opportunity announcement encourages innovative and high-risk/impact studies that may lead to breakthrough in mitochondrial function, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in understanding and treatment of mitochondrial dysfunction.



Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 10:10:23 EST

Funding Opportunity PA-18-099 from the NIH Guide for Grants and Contracts. This FOA encourages pilot and feasibility clinical and translational research studies of digestive and liver diseases.



Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 10:12:29 EST

Funding Opportunity PA-18-104 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program.



Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

Mon, 13 Nov 2017 09:51:21 EST

Funding Opportunity PA-18-286 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage submission of Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a new multidisciplinary approach to a biomedical challenge; 2) are high-risk but have high impact; and 3) develop data that may lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.



NIDCD Clinical Trials in Communication Disorders (R01-Clinical Trial Required)

Mon, 13 Nov 2017 01:48:29 EST

Funding Opportunity PA-18-334 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-18-340, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.



NINDS Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 10:40:45 EST

Funding Opportunity PA-18-358 from the NIH Guide for Grants and Contracts. The NINDS Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.



Addressing Health Disparities in NIDDK Diseases (R01 - Clinical Trial Not Allowed)

Fri, 17 Nov 2017 11:32:55 EST

Funding Opportunity PA-18-412 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Research is encouraged in the following high priority diseases: diabetes and other endocrine and metabolic diseases; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; complications of sickle cell disease within the NIDDK mission areas; kidney diseases; urologic diseases; metabolic, gastrointestinal, hepatic, and renal complications from infection with HIV; and mechanistic research in hematologic diseases, including studies in abnormal hemoglobin synthesis. This FOA will not support multi-center clinical studies or Clinical Trials. Animal research is allowed if the research is a clinically relevant model of a NIDDK mission area disease in a minority population.



Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 10:14:29 EST

Funding Opportunity PAR-18-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.



NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Fri, 17 Nov 2017 09:45:40 EST

Funding Opportunity PAR-18-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).



Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)

Fri, 17 Nov 2017 09:47:45 EST

Funding Opportunity PAR-18-081 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.



Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)

Fri, 17 Nov 2017 09:50:01 EST

Funding Opportunity PAR-18-082 from the NIH Guide for Grants and Contracts. This FOA will use an NIH Small Research Grant (R03) award mechanism and seeks to facilitate the entry of beginning investigators into the field of behavioral science research related to drug abuse. R03 projects will be supported for one year to allow gathering of pilot data with the intent that PDs/PIs become better positioned to seek additional support for independent research programs. To be appropriate for a B/Start award, research must be primarily focused on behavioral processes and research questions.



NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Optional)

Fri, 17 Nov 2017 09:52:02 EST

Funding Opportunity PAR-18-083 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/service providers, clinical researchers or optimally a combination of the two. This mechanism may not be used for support of non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences.



Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

Fri, 17 Nov 2017 10:04:47 EST

Funding Opportunity PAR-18-084 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.



Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R33 Clinical Trial Optional)

Fri, 17 Nov 2017 10:08:26 EST

Funding Opportunity PAR-18-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).



Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

Fri, 17 Nov 2017 10:10:35 EST

Funding Opportunity PAR-18-086 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).



Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 10:16:16 EST

Funding Opportunity PAR-18-100 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases.



Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)

Wed, 15 Nov 2017 10:29:30 EST

Funding Opportunity PAR-18-101 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders.



Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)

Fri, 17 Nov 2017 09:53:47 EST

Funding Opportunity PAR-18-102 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators from backgrounds nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The R21 is intended to support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of New Investigators from backgrounds underrepresented in the biomedical and behavioral sciences. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.



Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03 Clinical Trial Optional)

Fri, 17 Nov 2017 09:55:56 EST

Funding Opportunity PAR-18-103 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, and K23 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.



T1 Translational Research: Novel Interventions for Prevention and Treatment of Age-related Conditions (R21 Clinical Trial Optional)

Fri, 17 Nov 2017 10:12:44 EST

Funding Opportunity PAR-18-177 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages exploratory/developmental research projects to accelerate the pace of development of novel therapeutics involving biologics, pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical findings towards the development of new strategies for prevention and treatment of age-related pathologies.



T2 Translational Research: Research Leading to New Health Care Practices, Community Programs and Policies Affecting Older Persons (R21 Clinical Trial Optional)

Fri, 17 Nov 2017 10:15:08 EST

Funding Opportunity PAR-18-178 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages exploratory/developmental research projects on translational research (T2) directed towards development of health care practices, community programs and policies, including monitoring and quality improvement for pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T2 translational research on aging is defined as research to gather information needed to develop or evaluate methods of translating results from clinical studies into everyday clinical practice and health decision making (e.g., adapting an efficacious intervention for application in clinical practice and evaluating its effectiveness in different clinical settings). Methods for T2 translational research include but are not limited to intervention studies, systematic reviews, meta-analysis, outcomes research and implementation research.



Leveraging Electronic Health Records for Alcohol Services Research (R21/R33 Clinical Trial Optional)

Fri, 17 Nov 2017 10:18:35 EST

Funding Opportunity PAR-18-203 from the NIH Guide for Grants and Contracts. This FOA seeks low-cost, pragmatic research projects that leverage electronic clinical records to conduct studies that address novel health services questions about the treatment of alcohol use disorders (AUD) in routine clinical care settings. Although projects may be supplemented by other data sources, it is expected that major data collection activities will be integrated into, or obtained from, routine clinical records and other electronic resources, such as patient registries, electronic health records, data warehouses, billing data, pharmacy records, and/or administrative records. Projects should address questions with direct relevance for improving clinical care for patients with AUD, while contributing to an understanding of the current utility and remaining barriers to using electronic health records in the conduct of AUD treatment services research.



NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

Fri, 17 Nov 2017 10:20:58 EST

Funding Opportunity PAR-18-207 from the NIH Guide for Grants and Contracts. This Trailblazer Award is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and behavioral sciences. This FOA invites applications from researchers who are at the early stage of their independent careers or those who have not had substantial prior NIH funding. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data.



Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)

Fri, 17 Nov 2017 10:23:31 EST

Funding Opportunity PAR-18-227 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.



Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R34 Clinical Trial Required)

Fri, 17 Nov 2017 10:25:22 EST

Funding Opportunity PAR-18-228 from the NIH Guide for Grants and Contracts. This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population.



Pilot Services Research Grants Not Involving Interventions (R34 Clinical Trial Optional)

Fri, 17 Nov 2017 10:27:06 EST

Funding Opportunity PAR-18-267 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot research consistent with NIMH priorities for services research studies that are not immediate precursors to the development and testing of services interventions.While NIMH has moved to supporting all interventions research under FOAs that require use of an experimental therapeutics model, there is recognition that some important areas of mental health services research fall outside of that domain and have the potential to make significant contributions to advancing NIMH priorities and objectives.These areas include: 1) studies to identify mutable factors that impact access, utilization, quality, financing, outcomes including disparities in outcomes, or scalability of mental health services, which may serve as targets in future intervention development; 2) development and testing of new research tools, measures, or methods; or 3) testing the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care.



NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01-Clinical Trial Required)

Mon, 13 Nov 2017 01:48:25 EST

Funding Opportunity PAR-18-340 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, has annual direct costs equal to or greater than $500,000, that is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PA-18-334



NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (R25 - Clinical Trial Not Allowed)

Mon, 13 Nov 2017 10:03:44 EST

Funding Opportunity PAR-18-346 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Insitute of Neurological Disorders and Stroke R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences, designed to foster the development of physicians as research scientists in areas relevant to the NINDS mission. The research experiences will prepare clinicians to successfully compete for individual NIH mentored career development awards, or where appropriate, independent research awards. This FOA will also support educational activities such that participants of the R25 are expected to attend and participate in an annual workshop specific to this FOA to present their work, discuss progress and plans towards transitioning to the next career stage and to network with other researchers and leaders in their fields. Such success will facilitate their transition from resident/fellow to physician-scientist, and will thus foster retention of a cadre of physician-scientists who will conduct research into the mechanisms of, etiology, and treatment of neurological diseases.



NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)

Wed, 15 Nov 2017 02:22:24 EST

Funding Opportunity PAR-18-359 from the NIH Guide for Grants and Contracts. The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-321).



NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22-Clinical Trial Required)

Wed, 15 Nov 2017 03:36:22 EST

Funding Opportunity PAR-18-360 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-140).



Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)

Wed, 15 Nov 2017 04:22:44 EST

Funding Opportunity PAR-18-361 from the NIH Guide for Grants and Contracts. This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations. The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities.



NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

Fri, 17 Nov 2017 12:32:27 EST

Funding Opportunity PAR-18-364 from the NIH Guide for Grants and Contracts. The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.



NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

Fri, 17 Nov 2017 12:32:25 EST

Funding Opportunity PAR-18-365 from the NIH Guide for Grants and Contracts. The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.



Getting to Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Not Allowed)

Thu, 16 Nov 2017 09:13:28 EST

Funding Opportunity PAR-18-411 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve measurement and understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology and novel tools from Big Data science approaches and m/eHealth. The outcome of this research will uncover new knowledge from data to build more effective and context-specific HIV control strategies for the U.S. epidemic.



Mechanistic Basis of Diffuse White Matter Disease and Small Vessel Pathology in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01)

Fri, 17 Nov 2017 11:49:30 EST

Funding Opportunity PAR-18-413 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease and small vessel disease in the brain, the relationships between them, and how they may contribute to cognitive impairment and dementia.